Navigation Links
Inflammatory Bowel Diseases (IBD): World Drug Industry and Market 2015-2025

LONDON, January 22, 2015 /PRNewswire/ --

Report Details 

Treating Crohn's disease and ulcerative colitis - how to find R&D trends, opportunities and revenue prospects 

What's the future of medicines for inflammatory bowel disease (IBD)? Those intestinal treatments retain high potential. Now you can explore sales forecasts and that industry's research and development. See there how that large, profitable market expands.

Visiongain's new investigation predicts those revenues to 2025 at overall world market, submarket, product and national level. Its purpose is to give data and analysis on therapies, assessing medical, technological and commercial potentials and opportunities.

Find where the most money and best prospects for business growth exist. Please read on to examine those colonic treatments, seeing how high that industry's sales can go.

Forecasts and other analyses to help your gastrointestinal drug research, knowledge and influence 

Avoid struggles to find that business information. Instead discover what's happening in treating those lower digestive tract disorders. Now you can make your research, appraisals and decisions for the IBD market quicker and easier, also seeing where the money lies.

Besides revenue forecasting to 2025, our new report gives you commercial results, growth rates, market shares and discussions. There you get two interviews, 42 charts and 92 tables.

Discover how competition and technological advances shape that industry. Also benefit your reputation for knowledge. See what's possible from now and how you can gain.

To see a report overview please email Sara Peerun on

Forecasting of that world market and five therapeutic segments for those intestinal disorders 

Our study predicts overall world revenue to 2025 for those anti-IBD drugs. There you also find individual revenue predictions to 2025 for five submarkets at world level:
• Biologics
• Aminosalicylates
• Antibiotics
• Corticosteroids
• Immunomodulators.

You investigate the most promising and lucrative parts of that industry. Gaining a feel for opportunities, hear how those therapies can progress. You explore how, where, when and why rapid market expansion can occur.

For those medications, our analyses also investigate prominent brands.

Forecasts for 17 top products - discover sales potentials 

How will leading drugs perform to 2025 at world level? Our study forecasts individual revenues of 17 prominent agents for those colonic disorders, including these agents:
• Humira (adalimumab)
• Remicade (infliximab)
• Asacol (mesalazine)
• Lialda (mesalamine)
• Tysabri (natalizumab)
• Cimzia (certolizumab pegol).

You also discover selling potentials of emerging therapies Simponi (golimumab), Uceris (budesonide) and Entyvio (vedolizumab). There you see prospects for monoclonal antibodies - leading biological drugs.

Our study shows how high sales can go, to 2025, revealing medicines and years with highest predicted growth and revenues. Treating large-intestine disease holds much commercial potential. And you find what the future holds for treating inflamed bowel.

You also discover geographical revenue predictions.

Healthcare in national markets - what outlooks for selling those pharmaceuticals? 

Our study shows you individual revenue forecasting to 2025 for 11 countries:
United States (US)
Germany, France, UK, Italy and Spain (EU5 group)
Brazil, Russia, India and China (BRIC nations).

There you find countries with highest IBD revenues, demand and potential sales. Investigate progress, needs and opportunities, seeing how you can gain.

And how do changes, challenges and technological advances affect that biopharma industry and market?

Forces, events and issues - developments influencing those treatments and their producers 

That new analysis explains policies, trends and R&D shaping that industry and market, including these influences:
• Aetiology, disease incidence, prevalence and diagnosis
• Prospects for developing interleukin (IL), cell-adhesion molecule (CAM), JAK and TNF inhibitors - discovering and testing molecular targets
• Progress in stem cells and toll-like receptor agonists - emerging therapy
• Monoclonal antibodies (mAbs) and biosimilars (follow-on protein products) - see their prospects for changing that gastrointestinal (GI) sector
• Delivery systems for agents treating those medical conditions - advances in supporting technology.

In 2014 there exist 37 promising new agents with various mechanisms of action, and nine proposed biosimilar molecules in clinical trials for Crohn's disease and ulcerative colitis.

Our study gives you feel for that market - its progress and potential. Also you discover what stimulates and restrains that industry. That way you're less likely to fall behind.

To see a report overview please email Sara Peerun on

Treatments for inflamed lower intestine - prominent companies and 2018 market value 

What happens next? From 2015 IBD medicines hold great potential for investments, technologies, medical advances and sales. Our new report predicts the world market for those products will reach $10.2bn in 2018, with strong revenue growth from 2014.

That work also explores activities, results and potentials of top companies, especially these firms:
• AbbVie
• Janssen Biotech
• Actavis
• Shire Pharmaceuticals.

With our study you see how that market can develop and perform, benefiting your insight and authority. See, then, how you can benefit your research, analysis and planning.

Ways Inflammatory Bowel Diseases (IBD): World Drug Industry and Market 2015-2025 helps 

That new investigation benefits your work in eight main ways:
• World market revenue to 2025 - discover that industry's overall sales potential
• 5 product classes' revenues to 2025 - investigate categories at world level, finding the most lucrative and promising groups
• 17 leading drugs' revenues to 2025 - find sales predictions for top therapies, seeing how they can compete and succeed
• 11 national markets in the Americas, Europe and Asia, with forecasts to 2025 - discover the best countries for business expansion
• Activities of established, rising and emerging companies - hear about firms' products, capabilities, advances and outlooks
• Research and development - investigate progress in that industry, exploring technological, clinical and commercial opportunities
• Interviews with two organisations - discover other experts' views, developing your understanding
• Analysis of what stimulates and restrains the IBD-treating drug market - assess challenges, strengths and opportunities there, helping you succeed.

That study gives original business intelligence - knowledge found only there.

Trying our analysis now lets you discover trends, opportunities and sales forecasts
Our new assessment shows you results, trends and opportunities. There you gain multilevel annual predictions to 2025 for inflammatory bowel medicines, seeing where the money lies. Avoid missing out. Instead please get that study here now.

To request an exec summary of this report please email Sara Peerun at or call Tel: +44-(0)20-7336-6100

Or click on

Companies Listed on this report 

Abbott Laboratories
Active Biotech
Aga Khan University Hospital, Karachi, Pakistan
Aptalis Pharmaceuticals
Atlantic Healthcare
Avaxia Biologics
Boehringer Ingelheim
Center for Human Disease Research, Leiden
Centocor Ortho Biotech
Centrale Commissie Mensgebonden Onderzoek (CCMO)
Centres for Disease Control and Prevention (US)
Coherus Biosciences
Coronado Biosciences
Cosmo Pharmaceuticals
Crohn's and Colitis Foundation of Canada
Dr. Falk Pharma
Elan Pharmaceuticals
Epirus Biopharmaceuticals
European Medicines Agency (EMA)
Food and Drug Administration (US FDA)
Forest Laboratories
Harbor Biosciences
Hebrew University of Jerusalem
InDex Pharmaceuticals
Infinity Pharmaceuticals
Institut National de la Santé et de la Recherche Médicale (INSERM)
Isis Pharmaceuticals
Janssen Biotech
Johnson & Johnson
Karolinska Institute
LG Sciences
Mylan Pharmaceuticals
National Health Service (UK NHS)
National Institute for Health and Care Excellence (UK NICE)
National Institutes of Health (US NIH)
Nisshin Kyorin
Nogra Pharma
Ortho Biotech
Osiris Therapeutics
Palau Pharma
Pluristem Therapeutics
Quest Diagnostics
Ranbaxy Laboratories
RedHill Biopharma
Reliance Life Sciences
Salix Pharmaceuticals
Servicio Sanitario Nazionale (SSN, Italy)
Shire Pharmaceuticals
Sigmoid Pharma
Takeda Pharmaceuticals
Teva Pharmaceutical Industries
The Crohn's and Colitis UK Foundation
The European Federation of Crohn's and Ulcerative Colitis Associations
Toray Industries
Warner Chilcott
Zydus Cadila

To see a report overview please email Sara Peerun on

SOURCE Visiongain
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Receptos to Deliver Scientific Presentation at Digestive Disease Week 2012 about the Therapeutic Role of RPC1063 in Inflammatory Bowel Disease
2. Rheumatoid Arthritis New Major Clinical Target After Mesoblast Obtains Positive Results in Inflammatory Arthritis
3. Prometheus Launches New Monitoring Test To Help Guide Inflammatory Bowel Disease Management
4. Imprimis Pharmaceuticals Signs Agreement With DPT Labs For Clinical Supplies In Advance Of Planned Phase 3 Studies For Its Ketoprofen-Based Topical Anti-Inflammatory Drug
5. Soligenix Announces Issuance of US Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders
6. Grant Awarded to Study Novel Therapies for Muco-Obstructive Diseases Includes Studies on Cempras Solithromycin (CEM-101) in a Cystic Fibrosis Anti-inflammatory Model
7. The Kenneth Rainin Foundation Continues its Commitment to Ending Inflammatory Bowel Disease, Awarding $1.5 Million in Research Grants
8. Gastroenterologists Unlikely To Use Celltrion/Hospiras Infliximab Biosimilar Due To Lack Of Clinical Data In Inflammatory Bowel Disease
9. Rheumatology Network Presents Latest Advances Against Baffling Inflammatory Diseases From Major Rheumatology Conference
10. BioLineRx Announces New Positive Results in Phase 2a trial for Orally Available Inflammatory Bowel Disease Treatment
11. Shield Therapeutics ST10 Delivers Robust Results Meeting both Primary and Secondary Endpoints in the Pivotal AEGIS Phase 3 Programme for the Treatment of Iron Deficiency Anaemia in Inflammatory Bowel Disease
Post Your Comments:
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, Inc. ... earnings conference call and webcast on Friday, November 3, ... (EDT) and ending at approximately 8:30 a.m. (CDT) / ... the company,s 2017 financial performance and guidance for 2018, ... initiatives to enhance operational performance, and long-range financial outlook ...
(Date:9/25/2017)... , Sept. 25, 2017   Montrium ... Master File solutions, today—from the IQPC Trial Master ... , NL)—announced that EastHORN Clinical Services has ... clinical programs and TMF management. EastHORN, a leading ... eTMF platform to increase transparency to enable greater ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 13, 2017 , ... The American Board of Family Medicine's (ABFM) Board of ... Executive Officer, succeeding Dr. James C. Puffer upon his retirement. Dr. Newton will serve ... Puffer’s retirement at the end of 2018. Upon assuming the role of President and ...
(Date:10/13/2017)... ... 2017 , ... PurhealthRX , a leading Health and Nutrition Company, is ... to full spectrum CBD oil will revolutionize the rapidly growing CBD market by reducing ... easily incorporated into liquid products, while reducing costs to end users. , The team ...
(Date:10/13/2017)... ... ... Lori R. Somekh, founder of the Law Office of Somekh & Associates ... special needs planning attorneys. “Membership in ElderCounsel helps our office remain up to date ... elder law attorneys nationwide,” said Somekh. , ElderCounsel was founded by ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers ... companies have a waiver for care if the client has a cognitive impairment diagnosis. ... pays for care, is often waived, so the benefits from their insurance start immediately,” ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading ... to advocate for action towards gender equality at their inaugural Summit in New York ... globe, and reached a social audience of over 3 million. To watch the Mobilize ...
Breaking Medicine News(10 mins):